Radiopaque, optically translucent thermoplastic compounds
A radiopaque, optically translucent thermoplastic polyurethane compound is disclosed. The use of nano-sized particles of barium sulfate optionally in combination with a minor amount of certain dispersion aids allows the barium sulfate to be sufficiently dispersed within the thermoplastic polyurethane to retain optical translucency according to a defined Haze Determination Test. Medical devices, needing both visual spectrum observation before and during in-vivo medical use and radiopacity monitoring during in-vivo medical use, benefit from this compound. Optionally, a surface enhancer can also be used.
1. A radiopaque, optically translucent thermoplastic compound, comprising:
(a) thermoplastic polyurethane;
(b) nano-sized particles of barium sulfate dispersed in the thermoplastic polyurethane at about 19 weight percent to 50 about 21 weight percent of the compound, wherein the nano-sized particles of barium sulfate have more than 50% of primary particles of the barium sulfate in a size in a largest dimension of less than or equal to 100 nanometers;
(c) dispersion aid at about 1 weight percent to about 4 weight percent of the compound, wherein the dispersion aid is selected from the group consisting of 1,2-propylene glycol, 1,3-propylene glycol, sulfolane, triethyl citrate, 1-methyl-2-pyrrolidinone, and combinations thereof; and
(d) surface enhancer at about 1 weight percent to about 3 weight percent of the compound, wherein the surface enhancer is selected from the group consisting of fatty acids, fatty acid esters, and combinations thereof;
wherein a compressed film of the compound in a thickness of 0.18 mm has a haze of less than 70%, as measured using a Haze Determination Test.
2. The compound of claim 1 , wherein the compressed film has a haze of less than 30%, as measured using the Haze Determination Test.
3. The compound of claim 1 , wherein the dispersion aid is 1,2-propylene glycol or 1,3-propylene glycol or combinations thereof, and wherein the compressed film has a haze of less than 30%, as measured using the Haze Determination Test.
4. The compound of claim 1 , wherein the fatty acid is stearic acid and wherein the fatty acid ester is glycerol monostearate.
5. A medical device made from the compound of claim 1 .
6. The medical device of claim 5 , in the form of a catheter.
7. The medical device of claim 5 in the form of tubing.
8. A radiopaque, optically translucent thermoplastic compound, comprising:
(a) thermoplastic polyurethane;
(b) nano-sized particles of barium sulfate dispersed in the thermoplastic polyurethane at about 15 weight percent to about 25 weight percent of the compound, wherein the nano-sized particles of barium sulfate have more than 50% of primary particles of the barium sulfate in a size in a largest dimension of less than or equal to 100 nanometers; and
(c) dispersion aid at about 1 weight percent to about 4 weight percent of the compound, wherein the dispersion aid is selected from the group consisting of 1,2-propylene glycol, 1,3-propylene glycol, and combinations thereof;
wherein a compressed film of the compound in a thickness of 0.18 mm has a haze of less than 30%, as measured using a Haze Determination Test.
9. The compound of claim 8 , wherein the dispersion aid is 1,2-propylene glycol, wherein the compound further comprises surface enhancer at about 1 weight percent to about 3 weight percent of the compound, and wherein the surface enhancer is glycerol monostearate.
10. A medical device made from the compound of claim 9 .
11. The medical device of claim 10 , wherein the medical device is in the form of a catheter or tubing.